Medicare Expands Coverage for GLP-1 Medications for Obesity
Medicare is set to introduce coverage for specific GLP-1 medications focusing on weight loss related to obesity, marking a significant shift in policy. This change will enable eligible Medicare beneficiaries to access treatments like Foundayo by Eli Lilly and Wegovy by Novo Nordisk, starting at $50 per month with a prescription from this Wednesday. The initiative stems from a federal pilot program approved by the Health and Human Services Secretary, with plans to run through December 31, 2027.
This program emerges as a key change since Medicare Part D has not traditionally covered drugs solely for weight loss. With the introduction of this bridge program, there's potential to broaden the availability of these medications, aiding seniors in managing obesity—a concern heightened by existing high costs that previously limited access. Dr. Mehmet Oz, administrator of the Centers for Medicare and Medicaid, noted that this effort seeks to enhance affordability and access to improve older Americans' health.
The initiative is expected to impact approximately 3.8 million Medicare beneficiaries, based on 2023 Part D enrollment data analyzed by the Kaiser Family Foundation. An agreement with pharmaceutical manufacturers sets a government-covered price at $250 monthly, expanding treatment availability. Beneficiaries will have a copayment of $50 per month, which does not contribute to their annual deductible. However, pre-authorization is essential, needing documentation from prescribing clinicians to confirm eligibility based on specific body mass index (BMI) and health conditions.
Program eligibility extends beyond BMI to include additional health criteria. Beneficiaries with a BMI between 30 and 35 must show conditions such as specific heart issues or renal disease, while those with a BMI of 27 to 30 need conditions like prediabetes or a history of cardiovascular events. These requirements are more stringent compared to FDA-approved labels or common private insurance guidelines.
Individuals already covered for GLP-1 medications for other conditions, such as type 2 diabetes, are excluded from this bridge program. Chris Klomp, director of Medicare and chief counselor at the U.S. Department of Health and Human Services, highlighted the program's potential benefits, noting it aims to enhance access consistency and predictability across Medicare.
Approved prescriptions can be filled at local retail pharmacies or via direct mail order services offered by Novo Nordisk or Eli Lilly. This development signifies a potential shift in the approach to drug coverage under Medicare, potentially affecting market dynamics and operational practices within the insurance and pharmaceutical sectors.